Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow INDV
Indivior Pharmaceuticals Inc. (INDV) EV/Sales
As of 16 October 2026, Indivior Pharmaceuticals Inc. (INDV) trades at a EV/Sales of 3.1×. Over the past ten years it has ranged from −0.6× (January 2020) to 4.3× (June 2026); the current reading is higher than 87% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | 167.21% |
| FY2024 | 1.4× | (21.95%) |
| FY2023 | 1.8× | (32.21%) |
| FY2022 | 2.6× | 25.93% |
| FY2021 | 2.1× | 200.14% |
| FY2020 | 0.7× | — |
| FY2019 | −0.6× | — |
| FY2018 | 0.3× | (90.94%) |
| FY2017 | 3.3× | 44.68% |
| FY2016 | 2.3× | 9.86% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.9× | 21.79% |
| Mar 2026 | 3.2× | (14.15%) |
| Dec 2025 | 3.7× | 51.85% |
| Sep 2025 | 2.4× | 73.27% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| INDV Indivior Pharmaceuticals Inc. | 3.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| LQDA Liquidia Corporation compare | 6.5× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 30.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)